BACKGROUND: Gaucher disease (GD) is an inherited, rare, lysosomal storage disorder caused by a genetic deficiency of glucocerebrosidase. The result is the accumulation of the substrate, glucosylceramide, in the lysosomes of macrophage cells in the liver, spleen, bones, lungs, and other vital tissues. Three subtypes of Gaucher disease are recognized: type 1 (GD1, non-neuropathic), type 2 (GD2, acute neuropathic), and type 3 (GD3, subacute/chronic neuropathic). Clinical manifestations of the disease are multi-systemic, clinically heterogeneous, and require lifelong management.
Background
• Gaucher Disease (GD) is an inherited, autosomal recessive disorder, and is the most common lysosomal storage disease (LSD). 1 GD results from mutations in the glucocerebrosidase (a glucosylceramidase, also known as acid beta-glucosidase) gene (GBA), leading to deficiency of enzyme activity or protein function. 2 • GD is a lifelong, progressive disease characterized by accumulation of sphingolipid glucosylceramide in macrophage lysosomes in the liver, spleen, bones, lungs, and other tissues, leading to severe complications if left untreated. 1 • GD is rare in the general population (global prevalence ~1 case per 111,111 people 2 ), but disproportionately affects persons of Ashkenazi Jewish descent, where prevalence is estimated at 1 in 855 individuals. 2 • Type 1 GD (non-neuropathic) affects the skeleton, viscera, and blood cells; types 2 (acute neuropathic) and 3 (subacute/chronic neuropathic) affect the nervous system as well as the systems involved in type 1, with differing ages of onset and disease progression. All three types require lifelong management. 2, 3 • Annual monitoring of GD requires clinical examination, and magnetic resonance imaging (MRI), computerized tomography (CT), and dual-energy X-ray absorptiometry (DXA) scans to assess liver, spleen, and skeletal manifestations, burdening patients significantly in costs and time.
2
• GD treatment has been revolutionized since 1990 with the introduction of intravenous enzyme replacement therapy (ERT) and oral substrate reduction therapy (SRT) to decrease glucosylceramide levels in the liver, spleen, and other organs.
3
• ERT and SRT improve hemoglobin levels and platelet counts, decrease spleen and liver size, relieve symptoms of bone disease, and improve health-related quality of life (HRQOL).
• Severe GD patients may require additional treatment options including analgesics for bone pain, blood transfusions, orthopedic surgery, and, rarely, splenectomy or bone marrow transplantation.
2
• We conducted a comprehensive review of published evidence to better understand the epidemiologic, clinical, and socioeconomic burden of GD.
Methods
• MEDLINE, EMBASE, CENTRAL, and "grey" literature were searched to identify English-language studies of interest published between 1990 and February 2013.
• Supplemental searches identified unpublished material (e.g., meeting proceedings) and publications not captured by the initial search strategy.
• Eligible studies examined the epidemiology, clinical, or socioeconomic burden of GD, or current treatment options. Studies investigating in vitro, animal, fetal, genetic, or pharmacokinetic (PK)/pharmacodynamics (PD) outcomes, biomarker studies, and studies involving fewer than five patients were excluded.
• Overall, 2034 citations were identified through a systematic keyword search of databases, conference abstracts, and manual searches of published reviews. 
Results

The Epidemiology of GD
• Of the 9 studies that reported prevalence, 4 studies reported prevalence in all-ages general populations. 4-7,11 1 study screened Ashkenazi Jewish newborns, 12 and the remaining studies reported birth prevalence, retrospectively. [7] [8] [9] • All GD types were far more prevalent among Ashkenazi Jewish populations (82.8 to 222.2 per 100,000 [11] [12] ) than general European and Australian populations (0.33 to 1.75 per 100,000; Figure 2 ). • Incidence of GD also varied among general-population studies in Europe, Asia, and Canada, ranging from 0.30 to 5.80 per 100,000 ( Figure 3 ).
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• The highest GD incidence among the general population was in Austria (5.80 per 100,000). The study screened newborns for LSD-specific genetic mutations, and this resulted in more cases of GD being diagnosed in this population than might ordinarily have been the case with purely clinical ascertainment.
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• A genetic study screening Ashkenazi Jewish couples in Israel reported 83 instances where both partners were carriers for GD mutations. Prenatal diagnosis for GD was performed in 68 pregnancies for 65 carrier couples; sixteen (24%) were diagnosed with type 1 GD. 18 
Clinical Manifestations and Comorbidities in Untreated GD
• Data on clinical manifestations and comorbidities were from genetic, hospital, or tertiary care cohorts, screening studies, real world evidence studies (except for hematologic manifestations), the International Collaborative Gaucher Group registry, and national disease registries. 
Hematologic Manifestations of GD
• In GD patients prior to ERT or SRT, anemia was present in 11-75% and thrombocytopenia in 20-62% ( Table 1) .
Visceral Manifestations of GD
• Prevalences of splenomegaly and hepatomegaly varied widely among small samples of patients with untreated GD (15-96% and 10-86%, respectively) ( Table 1 ).
• A US study of 37 previously undiagnosed affected individuals of Ashkenazi Jewish descent reported a 97% prevalence of splenomegaly, with most cases described as mild. 19 
Skeletal Manifestations of GD
• Bone pain and bone crises were reported frequently in patients with untreated GD (8.0-64.2% and 3.4-24.2%, respectively) ( Table 1 ).
• The International Collaborative Gaucher Group Registry (1991-2011) reported that skeletal manifestations such as bone pain and bone crisis were more prevalent in splenectomized patients than non-splectomized patients.
20
Comorbidities in GD
• Parkinson's disease and cancer were frequently reported medically important comorbidities among patients with GD, suggesting increased risk or a possible cause-and-effect relationship ( Table 1) .
3
Mortality, HRQOL, Economic Burden and Unmet Needs of GD
• The risk of mortality was found to be highest in younger (<5 years of age) GD patients and also increased after age 55.
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• The reported life expectancy of patients with type 1 GD was 8.9 years lower than that of the overall US population.
• HRQOL scores were lower in untreated type 1 GD patients than in the general population. [22] [23] • Several studies have suggested that ERT improved HRQOL in patients with type 1 GD, with post-treatment scores comparable to those of the general population. [22] [23] [24] • UK researchers recently estimated the annual cost of care for GD patients, attributing four-fifths to the use of hospital services, of which ~50% were for outpatient visits. 24 The available evidence indicated that GD complications improve after the initiation of ERT.
• Limited studies assessed the direct medical costs of GD, and evidence on the indirect costs, healthcare use, and caregiver burden for GD are currently unavailable.
• Clinical unmet needs exist in GD, such as treatments for patients unresponsive to ERT, alternatives to intravenous infusion, and prompter diagnosis and treatment that can ameliorate disease progression and further complications.
Conclusions
• GD is a rare genetic disorder with significant morbidity and burden to patients and caregivers.
• The most common GD manifestations in untreated patients are anemia, thrombocytopenia, splenomegaly, hepatomegaly, bone disease, and bone pain.
• Current ERT can ameliorate many manifestations of GD and lead to improved HRQOL of type 1 GD patients
• Additional studies examining type 2 and type 3 GD, treatment-related HRQOL, and economic outcomes, including indirect costs in GD patients and caregivers, are required to more fully understand the current burden of the disease.
